BEIJING, April 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing
developer, manufacturer and seller of medicine and drugs in the People's
Republic of China (the "PRC") today reported that its innovative asthma drug
Laevo-Bambuterol has received approval from China's State Food & Drug
Administration's (SFDA) to commence clinical trials (No.2010L01309 and
2010L01399).

R-Bambuterol(R) Hydrochloride Tablets ("Laevo-Bambuterol") is categorized
as a Class 1 new drug. Its preclinical studies show that it is more effective
and have lower toxicity than Bambuterol, a popular asthma drug currently on
the market.

The Company is communicating with experts from the SFDA's Drug Review and
Evaluation Center on the designs for clinical trials and expects the new
product to launch in 2013-2014.

Safe Harbor Statement

This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may," or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
could cause the actual results of the Company to differ materially from the
results expressed or implied by such statements, including, but not limited to,
changes from anticipated levels of sales, future national or regional economic
and competitive and regulatory conditions, changes in relationships with
customers, access to capital, increased costs, difficulties in developing and
marketing new products, marketing existing products, customer acceptance of
existing and new products, the time to get new drugs approved by the State
Food and Drug Administration and other factors. Additional information
regarding risks can be found in the Company's Annual Report on Form 10K and
its other filings with the SEC. Accordingly, although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, there can be no assurance that such expectations will prove to be
correct. The Company has no obligation to update the forward-looking
information contained in this press release.

Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs
and a licensed national seller of pharmaceutical items in the PRC. Lotus
operates its business through its two controlled entities: Liang Fang
Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current
drug development is focused on the treatment of cerebro-cardiovascular disease,
asthma, and diabetes. Liang Fang sells drugs directly and indirectly through
its national sales channels to hospitals, clinics and drugs stores in 30
provinces of the PRC.

(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...

(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...

(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...

(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...